MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
MAIA (NYSE American: MAIA) announced on October 7, 2025 a new digital asset treasury strategy permitting corporate officers to buy and sell Bitcoin (BTC), Ethereum (ETH) and USD Coin (USDC).
The Board authorized holdings of up to 90% of the company’s liquid assets in cryptocurrencies and will review transactions, cybersecurity, accounting policies, risks, and material developments. Management said it will keep adequate working capital for operations and seek Board approval to form a Digital Assets Advisory Board to support execution.
MAIA (NYSE American: MAIA) ha annunciato il 7 ottobre 2025 una nuova strategia di tesoreria per asset digitali che consente agli ufficiali aziendali di comprare e vendere Bitcoin (BTC), Ethereum (ETH) e USD Coin (USDC).
Il Consiglio ha autorizzato una quota fino al 90% degli attivi liquidi dell’azienda in criptovalute e rivedrà le transazioni, la cybersicurezza, le politiche contabili, i rischi e gli sviluppi rilevanti. La direzione ha dichiarato che manterrà una liquidità operativa adeguata e cercherà l’approvazione del Consiglio per formare un Consiglio Consultivo sugli Asset Digitali per supportare l’esecuzione.
MAIA (NYSE American: MAIA) anunció el 7 de octubre de 2025 una nueva estrategia de tesorería de activos digitales que permite a los directivos comprar y vender Bitcoin (BTC), Ethereum (ETH) y USD Coin (USDC).
La Junta autorizó participaciones de hasta el 90% de los activos líquidos de la empresa en criptomonedas y revisará las transacciones, la ciberseguridad, las políticas contables, los riesgos y los desarrollos relevantes. La dirección dijo que mantendrá una liquidez operativa adecuada y buscará la aprobación de la Junta para formar un Consejo Asesor de Activos Digitales para apoyar la ejecución.
MAIA (NYSE American: MAIA) 는 2025년 10월 7일에 기업 임원이 비트코인(BTC), 이더리움(ETH), USD 코인(USDC)을 매매할 수 있도록 하는 새로운 디지털 자산 금고 전략을 발표했습니다.
이사회는 암호화폐로 회사 유동자산의 최대 90%를 보유하도록 승인했으며, 거래, 사이버 보안, 회계 정책, 위험 및 중대한 개발사항을 검토할 예정입니다. 경영진은 운영에 충분한 운전자본을 유지하고 실행을 지원하기 위해 디지털 자산 자문위원회를 구성하기 위해 이사회 승인을 구할 것이라고 밝혔습니다.
MAIA (NYSE American : MAIA) a annoncé le 7 octobre 2025 une nouvelle stratégie de trésorerie d’actifs numériques permettant aux responsables de l’entreprise d’acheter et de vendre Bitcoin (BTC), Ethereum (ETH) et USD Coin (USDC).
Le Conseil a autorisé des avoirs allant jusqu’à 90 % des actifs liquides de l’entreprise en cryptomonnaies et examinera les transactions, la cybersécurité, les politiques comptables, les risques et les développements importants. La direction a indiqué qu’elle maintiendrait une trésorerie opérationnelle adéquate et demanderait l’approbation du Conseil pour former un Conseil consultatif sur les actifs numériques afin de soutenir l’exécution.
MAIA (NYSE American: MAIA) kündigte am 7. Oktober 2025 eine neue Treasury-Strategie für digitale Vermögenswerte an, die es den Unternehmensführern erlaubt, Bitcoin (BTC), Ethereum (ETH) und USD Coin (USDC) zu kaufen und zu verkaufen.
Der Vorstand hat gehaltene Vermögenswerte von bis zu 90% der liquiden Mittel des Unternehmens in Kryptowährungen genehmigt und wird Transaktionen, Cybersicherheit, Buchhaltungsrichtlinien, Risiken und wesentliche Entwicklungen prüfen. Das Management sagte, es werde ausreichendes Betriebskapital für den Betrieb vorhalten und die Zustimmung des Vorstands einholen, um ein Digital Asset Advisory Board zu formieren, das die Umsetzung unterstützt.
MAIA (NYSE American: MAIA) أعلنت في 7 أكتوبر 2025 عن استراتيجية جديدة للسيولة تُتيح لموظفي الشركة شراء وبيع بيتكوين (BTC) وإيثيريوم (ETH) وUSD Coin (USDC).
المجلس وافق على حيازة ما يصل إلى 90% من أصول الشركة السائلة بالعملات الرقمية وسيراجع المعاملات، والأمن السيبراني، وسياسات المحاسبة، والمخاطر، والتطورات الجوهرية. وقالت الإدارة إنها ستحافظ على رأس مال تشغيلي كافٍ للعمليات وتطلب موافقة المجلس لتشكيل مجلس استشاري للأصول الرقمية لدعم التنفيذ.
MAIA (NYSE American: MAIA) 于 2025年10月7日 公布了一项新的数字资产金库策略，允许公司高管买卖 比特币 (BTC)、以太坊 (ETH) 和 USD Coin (USDC)。
董事会授权将最多 公司流动资产的90% 持有为加密货币，并将审查交易、网络安全、会计政策、风险和重大进展。管理层表示将保持充足的运营周转资金，并寻求董事会批准成立一个 数字资产咨询委员会 以支持执行。
- Board authorization for crypto strategy dated October 7, 2025
- Permission to hold BTC, ETH, and USDC as treasury assets
- Authorization allows up to 90% of liquid assets in crypto holdings
- Up to 90% allocation concentrates liquid assets in volatile crypto
- Management must address cybersecurity and accounting risks before trades
MAIA’s Board of Directors authorizes holdings of up to
CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets.
MAIA’s Board of Directors has authorized holdings of up to
“Our new digital assets treasury strategy focuses on diversifying our investment portfolio with leading and dynamic crypto tokens in the rapidly evolving blockchain space,” said MAIA CEO Vlad Vitoc, M.D. “We are taking a disciplined and measured approach, targeting only the highest-quality tokens to minimize risk while gaining exposure to those with the greatest potential for strong returns. This strategy offers another path to growing and sustaining value creation for our shareholders, which is always our top priority, while keeping adequate working capital for our business operations.”
MAIA also intends to have its Board approve the formation of a Digital Assets Advisory Board to support the execution of the digital asset treasury strategy.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
FAQ
What did MAIA (MAIA) authorize on October 7, 2025 regarding crypto?
Which cryptocurrencies will MAIA (MAIA) initially hold in its treasury?
How much of MAIA's liquid assets can be allocated to digital assets?
Will MAIA (MAIA) keep cash for operations after the crypto strategy?
What governance steps will MAIA take for its digital asset strategy?
What risks did MAIA (MAIA) highlight for its digital asset treasury plan?
